Assessing Eligibility for Anti‐Amyloid Treatment Among Primary Care Patients with Cognitive Symptoms
About 9-11% of patients undergoing cognitive evaluation in primary care are potentially eligible for anti-amyloid treatment under current clinical guidelines. Major exclusion factors included neuroimaging findings, anticoagulant use, and comorbidities. These findings may guide expectations around treatment uptake and support real-world health-economic analyses based on patient eligibility. At AAIC, we will present a proposed workflow to streamline identification of treatment candidates from primary to specialist care.
Authors
- Ayesha Fawad (ORCID: https://orcid.org/0000-0002-7918-5217)
- Erik Stomrud (ORCID: https://orcid.org/0000-0002-0841-5580)
- Pontus Tideman (ORCID: https://orcid.org/0000-0002-9620-7115)
- Danielle van Westen (ORCID: https://orcid.org/0000-0001-8649-9874)
- Beata Borgström Bolmsjö (ORCID: https://orcid.org/0000-0001-7655-0613)
- Oskar H. Hansson
- Niklas Mattsson‐Carlgren
- Josef Erik Barbosa Djärf
- Sebastian Palmqvist
- Ruben Smith
- Suzanne E. Schindler
Institutions
- Lund University (SE)
- Washington University in St. Louis (US)
- Skåne University Hospital (SE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108336
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00